Clinical Trials Logo

Advanced Malignant Mesothelioma clinical trials

View clinical trials related to Advanced Malignant Mesothelioma.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT01126346 Completed - Clinical trials for Unspecified Childhood Solid Tumor, Protocol Specific

Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

HOPE
Start date: May 2010
Phase: N/A
Study type: Interventional

RATIONALE: An orientation and patient education program and telephone counseling may help improve the quality of life in patients with peritoneal surface malignancies. PURPOSE: This clinical trial studies quality of life and survivorship care in patients undergoing surgery and chemotherapy for peritoneal surface malignancies.

NCT ID: NCT00459862 Completed - Clinical trials for Recurrent Malignant Mesothelioma

Pazopanib in Treating Patients With Malignant Pleural Mesothelioma

Start date: March 2007
Phase: Phase 2
Study type: Interventional

This phase II trial is studying the side effects and how well pazopanib works in treating patients with malignant pleural mesothelioma. Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT00392444 Completed - Clinical trials for Recurrent Malignant Mesothelioma

Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma

Start date: February 2007
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well sunitinib works in treating patients with advanced malignant mesothelioma of the pleura. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth.

NCT ID: NCT00365053 Completed - Clinical trials for Recurrent Malignant Mesothelioma

PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery

Start date: June 2006
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well PXD101 works as second-line therapy in treating patients with malignant mesothelioma of the chest that cannot be removed by surgery. PXD101 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT00309946 Completed - Clinical trials for Recurrent Malignant Mesothelioma

Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery

Start date: December 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well cediranib maleate works in treating patients with malignant mesothelioma that cannot be removed by surgery. Cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor

NCT ID: NCT00243074 Completed - Clinical trials for Recurrent Malignant Mesothelioma

S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery

Start date: November 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is study how well AZD2171 works in treating patients with malignant pleural mesothelioma that cannot be removed by surgery. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor

NCT ID: NCT00039182 Completed - Clinical trials for Recurrent Malignant Mesothelioma

Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung

Start date: May 2002
Phase: Phase 2
Study type: Interventional

Erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. This phase II trial is studying how well erlotinib works in treating patients with malignant mesothelioma of the lung

NCT ID: NCT00030498 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction

Start date: December 2001
Phase: Phase 1
Study type: Interventional

Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction. Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor

NCT ID: NCT00027703 Completed - Clinical trials for Recurrent Malignant Mesothelioma

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma

Start date: October 2001
Phase: Phase 2
Study type: Interventional

This randomized phase II trial is to see if combination chemotherapy works better with or without bevacizumab in treating patients who have malignant mesothelioma. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. It is not yet known if combination chemotherapy works better with or without bevacizumab in treating malignant mesothelioma.

NCT ID: NCT00025207 Completed - Clinical trials for Recurrent Malignant Mesothelioma

Gefitinib in Treating Patients With Malignant Mesothelioma

Start date: September 2001
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of gefitinib in treating patients who have malignant mesothelioma. Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of malignant mesothelioma